D-Pharm doubles on good interim stroke study results

The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.

The share price of D-Pharm Ltd. (TASE: DPRM) rose 117% in morning trading today to NIS 0.53, giving a market cap of NIS 24 million, after the company announced that it had obtained successful interim results in the Phase IIa clinical trial of its drug THR-18 taken in conjunction with tissue plasminogen activator (tPA) for the treatment of cerebral stoke. The interim report on the initial patients in the study states that the drug's safety profile allowed it to go forward with the second group of patients who will receive a higher dosage of the drug.

The randomized double-blind trial on 30 patients in three groups with increasingly higher dosages is being conducted at a medical center in Ukraine, and will be completed in the second half of 2014. The study's primary endpoint is to show that THR-18 is safe when taken in conjunction with tPA in cerebral stroke patients.

THR-18 is intended to decrease the risk of life threatening bleeding such as intra-cranial hemorrhage and brain edema in patients treated with the clot buster drug Alteplase (tPA). Alteplase, the only approved therapy for dissolution of blood clots in acute ischemic stroke, is also indicated for myocardial infarction and pulmonary embolism.

"Approval of the safety profile of the current dosage of THR-18 is encouraging. It allows us to move forwad to the higher dosage for cerebral stroke patients treated with tPA," said D-Pharm VP clinical development Dr. Gilad Rosenberg.

Published by Globes [online], Israel business news - www.globes-online.com - on March 4, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס